Viral hemorrhagic fevers (VHFs) refer to a group of illnesses that are caused by several distinct families of viruses. In general, the term "viral hemorrhagic fever" is used to describe a severe multisystem syndrome (multisystem in that multiple organ systems in the body are affected). Characteristically, the overall vascular system is damaged, and the body's ability to regulate itself is impaired. These symptoms are often accompanied by hemorrhage (bleeding); however, the bleeding is itself rarely life-threatening. While some types of hemorrhagic fever viruses can cause relatively mild illnesses, many of these viruses cause severe, life-threatening disease.
Viruses are insidious creatures. They differ from each other in many ways, and they can mutate - at times seemingly at will, as with HIV - to resist a host of weapons fired at them. Complicating matters further is that new viruses are constantly emerging.
Xcellerex, Inc. today announced that it has initiated a Phase I clinical trial of XRX-001, a novel, prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
NanoViricides, Inc. (the "Company"), reports that the Company has been invited to present on January 12th at the Biotech Showcase™, a conference designed to showcase promising companies and technologies for partnering and investment purposes.
TessArae, LLC, a privately held company, and Affymetrix Inc., (NASDAQ:AFFX) today announced that the Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to TessArae for its TessArray® Resequencing Influenza A Microarray Detection Panel for the Detection of the 2009 H1N1 Influenza A Virus (TessArray RM-Flu test) for the duration of the declaration of emergency unless revoked earlier. The declaration of emergency will expire on April 26, 2010, unless terminated earlier or renewed.
A Virology Lab in Children’s Hospital No. 1 (CH1), Ho Chi Minh City, Vietnam, sponsored by National Cheng Kung University Hospital (NCKUH) and National Health Research Institutes (NHRI) in Taiwan was launched on November 11th, 2009.
Peregrine Pharmaceuticals, Inc. today announced financial results for the second quarter of fiscal year (FY) 2010 ended October 31, 2009. Total revenue for the second quarter of FY 2010 increased 255% to $6,896,000, compared to $1,941,000 for the comparable prior year quarter.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and SNY), announced today the expansion of its dengue vaccine clinical program in Latin America with a new multicenter study in children and adolescent in Mexico, Colombia, Honduras and Puerto Rico. This new multicenter study complements an earlier study in Mexico and an ongoing study in Peru.
Scientists at The Scripps Research Institute have determined the structure of a critical protein from the Ebola virus, which, though rare, is one of the deadliest viruses on the planet killing between 50 and 90 percent of those infected.
NanoViricides, Inc., reports that the Company has filed its quarterly report with the SEC on November 23rd.
Human movement is a key factor of dengue virus inflow in Rio de Janeiro, according to results from researchers based at the Oswaldo Cruz Foundation (Fiocruz) in Brazil. The results, based on data from a severe epidemic in 2007-2008, contribute to new understanding on the dynamics of dengue fever in the second largest city in Brazil. Details are published November 10 in the open-access journal PLoS Neglected Tropical Diseases.
TessArae® LLC, a global leader in resequencing microarray-based applications, announces the launch of new integrated product solutions for genetic testing of the mutations that underlie human hereditary diseases. The combination of TessArae's expertise in microarray-based resequencing with novel nucleotide sequence basecalling algorithms and analysis software enables screening for all targeted mutations in multiple genes of a syndrome or disorder simultaneously.
Peregrine Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number 7,611,704, which includes broad claims covering anti-viral uses of phosphatidylserine (PS)-targeting antibodies including Peregrine's lead clinical compound, bavituximab. PS is a unique marker exposed on the surface of virally infected cells that can be targeted to treat a broad spectrum of virus infections.
Peregrine Pharmaceuticals, Inc. today announced that it has established a new Anti-Viral Research Group in its R&D organization.
Inviragen and SingVax have merged their complementary vaccine pipelines and their international product development capabilities to create a company that is developing a wide range of vaccines for infectious diseases prevalent in emerging economies.
AVI BioPharma, Inc. a developer of RNA-based drugs, announced today that it has received expanded contract funding of approximately $11.5 million from the Defense Threat Reduction Agency's (DTRA) Transformational Medical Technologies Initiative (TMTI) to support development of the Investigational New Drug (IND) data package for its candidate drug, AVI-7012, to treat Junin virus infection.
The U.S. plans to support efforts to develop a sustainable health system in Zimbabwe and increase its capacity to treat people, Eric Goosby, U.S. global AIDS Coordinator for PEPFAR, said on Wednesday after a visit to the country with USAID and CDC officials, according to a press release from the U.S. Embassy in Harare, Zimbabwe. Goosby said he is "optimistic" that the Zimbabwe PEPFAR team's experience will be used "to develop a response that fits the existing health infrastructure, supports it and reinforces it in a way that creates a durable and lasting response" (9/2).
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the first quarter of fiscal year (FY) 2010 ended July 31, 2009. Total revenues for the first quarter of FY 2010 increased 345% to $6,750,000, compared to $1,517,000 for the comparable prior year quarter. This increase was primarily generated from increased government contract revenue and from increased sales by Avid Bioservices, the company's wholly owned contract manufacturing subsidiary.
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic fever (VHF) infections.
Researchers at the University of Texas Medical Branch at Galveston have discovered two biochemical pathways that the Ebola virus relies on to infect cells.
Ghana's Ministry of Health recently launched the Nationwide Mosquito Control Programme (NAMCOP) in conjunction with the waste management company Zoomlion Ghana Limited, the Ghanaian Chronicle/allAfrica.com reports (Akweetey, Ghanaian Chronicle/allAfrica.com, 6/19).
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.